PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION. (23rd June 2022) - Dale, D. C.; Alsina, L.; Azar, A.; Badolato, R.; Bertrand, Y.; Deya, A.; Dickerson, K. E.; Ezra, N.; Hasle, H.; Kang, H. J.; Kiani-Alikhan, S.; Kuijpers, T.; et al.